The net profit in the first quarter was dark, and the sales structure attracted attention：
In the first quarter of this year, the performance list of in vitro diagnosis industry changed again. With a net profit of 2.682 billion yuan, Anxi biology surpassed Mindray medical and became the most profitable listed enterprise with its main business being IVD。
On June 20, an Xu biological released a record of investor relations activities to respond to the company's sales structure, capacity utilization, profit growth points in the post epidemic era and other issues。
On November 18, 2021, Anxi bio landed on the science and innovation board. On the same day, its novel coronavirus (2019 ncov) antigen self-test reagent obtained the EU CE certification。
Antigen reagents have brought substantial growth to the performance. In the first quarter of 2022, the company achieved a revenue of 5.474 billion yuan, an increase of 2763.42% year-on-year; The net profit was 2.682 billion yuan, a year-on-year increase of 3147.87%. The revenue and net profit in a single quarter have reached more than three times that of 2021。
According to an Xu biological disclosure, before the COVID-19, the company's flagship products were drug detection products. The detection methods include saliva detection, urine detection, whole blood detection, hair detection and powder detection, which provide products and solutions for the rapid detection of global drugs, and the number of product varieties ranks in the forefront of the world. Before the epidemic, the comprehensive gross profit margin of the company's overall products was about 50%。
It is worth noting that as of the end of the first quarter of 2022, the company's business revenue from the new crown accounted for 99.56% of the company's total operating revenue. In February this year, an Xu biological said in an investor survey that the company's new crown products are mainly sold in Canada, Australia, the European Union and other regions, with an average sales price of $1-2. At present, the monthly production capacity of the test box is expected to be about 260million people, and the monthly production capacity of the test pen is expected to be about 50million people。
When the black swan flies away, what is left of the enterprise
In the recent investor research activities, Anxi biology pointed out that the company's wholly-owned subsidiaries provide their own supplies of biological raw materials and medical plastic parts, and the industrial chain is relatively less dependent on external sources. In addition to self supply, biological raw materials will be developed and sold according to market demand in the future。
In the post epidemic era, novel coronavirus may exist as long as other respiratory disease viruses. The company will develop "two in one" or "three in one" joint detection reagents to detect a variety of respiratory diseases at the same time, such as covid-19, influenza, respiratory syncytia, etc. Among them, "covid-19 and influenza A and B antigen nasal detection kit (pen type)" has obtained EU CE certification, and has applied for registration certificates in many countries. In terms of drugs, focus on small molecule drugs and antibody drugs of covid-19, and look for good opportunities for participation。
Market growth is sluggish, where to look in the future？
Customs statistics show that from March to May this year, the export value of covid-19 reagent continued to decline, reaching only 1.394 billion yuan in May, less than one tenth of the export value in January.
According to the securities times, the import volume of covid-19 reagents from some countries that have relaxed epidemic prevention has decreased significantly. In addition, the price war is also staged overseas, and the selling price of antigen reagents is declining rapidly。
In China, covid-19 has just experienced the fifth round of price adjustment. According to the national regulations, the single person single test for nucleic acid detection has been reduced to no more than 16 yuan per person, and the multi person mixed test has been reduced to no more than 5 yuan per person. In some regions, the multi person mixed test has been reduced to more than 3 yuan per person, while the antigen reagent has been quoted at an ultra-low price of more than 2 yuan as early as one month ago. A number of enterprises were removed from the competitive sequence due to high online prices。
At the same time, the detection boom brought by the 15 minute nucleic acid sampling circle is also cooling down。
On June 9, at the press conference of the joint prevention and control mechanism of the State Council, it was clear that where there was no epidemic and no import risk, nucleic acid testing should not become a normal state. For more than a week, many places have successively cancelled regional normalized nucleic acid testing。
Enterprises are also actively looking for new exports。
According to the investor relations activity table disclosed by Mingde biology on June 16, with the end of the epidemic in the future, the strategic focus of the company will be readjusted to other business sectors except for covid-19 nucleic acid testing reagents. Previously, it has accumulated a lot of cash by taking advantage of public health events, and will actively invest in R & D and seek opportunities for extended development, and enter the cutting-edge technology fields such as in vitro diagnosis upstream raw materials, nanopore sequencing, and multiomics testing through investment, acquisition, and acquisition，
In the post epidemic era, whether IVD enterprises can quickly convert the previously accumulated capital and resources into new growth potential, and who can win in the new battlefield, remains to be tested by time.
The new crown business accounts for 99%, why do well-known machinery enterprises come here?
Nantong Factory Address: No.88 Yangcheng Road, Wuyao Town, Rugao City, Nantong City, Jiangsu Province
Shanghai Office Address: 259 Jiugan Road, Sijing Town, Songjiang District, Shanghai